Director/PDMR Shareholding

RNS Number : 8138V

Allergy Therapeutics PLC

07 November 2017

 

The announcement released by Allergy Therapeutics plc entitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as £0.0001 per share.  The correct exercise price is £0.001.  All other figures remain unchanged. The correct figure is included in the reissued announcement below:

07 November 2017

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Grant of Options under Long Term Incentive Plan

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2017, details of which were announced on 5 November 2014, have been met. Consequently, Allergy Therapeutics has today granted to certain employees of the Company, including a PDMR, low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP. Details of the grant of Options to the PDMR are as follows:

Director	Number of Ordinary Shares over which Options granted	Total number of Ordinary Shares over which Options granted	Total remaining number of Ordinary Shares provisionally  awarded under LTIPs
Manuel Llobet, Chief Executive Officer	626,399	626,399	1,690,000

The Options have been granted in accordance with the LTIP rules with an exercise price of £0.001 per share, and can be exercised between 07 November 2017 and 06 November 2027.

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Manuel Llobet
2	Reason for the notification Grant of Options
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ALLERGY THERAPEUTICS PLC
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of £0.001 each   GB00B02LCQ05
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	Exercise Price Volume £0.001 626,399
d)	Aggregated information - Aggregated volume - Price	626,399 Options £0.001
e)	Date of the transaction	07 November 2017
f)	Place of the transaction	London Stock Exchange, AIM

This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Philippa Gardner

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

DSHBDBDBRUGBGRR